Search
Eight childhood cancer researchers have been awarded over $2 million in transformative grants from Cancer Council WA to advance their pioneering work in improving cancer treatments and outcomes for patients in Western Australia and around the world.
Associate Professor Rishi Kotecha, Co-Head of Leukaemia Translational Research at The Kids Research Institute Australia Cancer Centre and Consultant Paediatric Oncologist at Perth Children's Hospital, has been named Cancer Council WA’s 2024 Cancer Researcher of the Year.
Dr Sébastien Malinge has received a Stan Perron Charitable Foundation Research Fellowship for his pioneering research, which is paving the way for safer, targeted therapies for children with hard-to-treat leukaemia
Cancer researchers have narrowed-down the field of immunotherapy drugs which could be used to tackle a form of childhood brain cancer.
The WA Kids Cancer Centre brings together clinicians and researchers working together to defeat childhood cancer.
Researchers have identified key differences between cancers that respond to immunotherapy and those that do not.
Congratulations to three outstanding The Kids Research Institute Australia researchers who have received second chance WA health funding designed to support researchers who have narrowly missed out on highly competitive national funding.
Dr Nick Gottardo, Co-Head of The Kids Research Institute Australia's Brain Tumour Research Team, has been announced a nominee for the 2018 WA Australian of the Year Award
The WA Kids Cancer Centre has secured $1.1 million in funding from the Medical Research Future Fund’s (MRFF) Paediatric Brain Cancer Research Stream 2 to develop more effective and less toxic treatments for rare brain cancers in infants.
Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA‐4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer types. However, as a monotherapy, objective responses only occur in a minority of patients. Chemotherapy is widely used in combination with immune checkpoint blockade (ICB). Although a variety of isolated immunostimulatory effects have been reported for several classes of chemotherapeutics, it is unclear which chemotherapeutics provide the most benefit when combined with ICB.